267 related articles for article (PubMed ID: 24561662)
41. New antithrombin-based anticoagulants.
Desai UR
Med Res Rev; 2004 Mar; 24(2):151-81. PubMed ID: 14705167
[TBL] [Abstract][Full Text] [Related]
42. Anticoagulant pharmacodynamics of tinzaparin following 175 iu/kg subcutaneous administration to healthy volunteers.
Barrett JS; Hainer JW; Kornhauser DM; Gaskill JL; Hua TA; Sprogel P; Johansen K; van Lier JJ; Knebel W; Pieniaszek HJ
Thromb Res; 2001 Feb; 101(4):243-54. PubMed ID: 11248285
[TBL] [Abstract][Full Text] [Related]
43. In vitro protamine neutralization profiles of heparins differing in source and molecular weight.
Racanelli A; Hoppensteadt DA; Fareed J
Semin Thromb Hemost; 1989 Oct; 15(4):386-9. PubMed ID: 2554498
[No Abstract] [Full Text] [Related]
44. Non-anticoagulant effects of low molecular weight heparins in inflammatory disorders: A review.
Yan Y; Ji Y; Su N; Mei X; Wang Y; Du S; Zhu W; Zhang C; Lu Y; Xing XH
Carbohydr Polym; 2017 Mar; 160():71-81. PubMed ID: 28115102
[TBL] [Abstract][Full Text] [Related]
45. [Determination of the anticoagulant activity of low molecular weight heparins by micellar electrokinetic chromatography combined with on-column enzymatic reaction].
Zhang M; Kang J
Se Pu; 2020 Oct; 38(10):1243-1248. PubMed ID: 34213123
[TBL] [Abstract][Full Text] [Related]
46. Comparative efficacy of different low-molecular-weight heparins (LMWHs) and drug interactions with LMWH: implications for management of vascular disorders.
Mousa SA
Semin Thromb Hemost; 2000; 26 Suppl 1():39-46. PubMed ID: 11011805
[TBL] [Abstract][Full Text] [Related]
47. Use of oral direct factor Xa inhibiting anticoagulants in elective hip and knee arthroplasty: a meta-analysis of efficacy and safety profiles compared with those of low-molecular-weight heparins.
As-Sultany M; Pagkalos J; Yeganeh S; Craigs CL; Korres N; West RM; Tsiridis E
Curr Vasc Pharmacol; 2013 May; 11(3):366-75. PubMed ID: 23140527
[TBL] [Abstract][Full Text] [Related]
48. In vitro studies on the biochemistry and pharmacology of low molecular weight heparins.
Jeske W; Fareed J
Semin Thromb Hemost; 1999; 25 Suppl 3():27-33. PubMed ID: 10549713
[TBL] [Abstract][Full Text] [Related]
49. Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile.
Fareed J; Hoppensteadt D; Schultz C; Ma Q; Kujawski MF; Neville B; Messmore H
Curr Pharm Des; 2004; 10(9):983-99. PubMed ID: 15078128
[TBL] [Abstract][Full Text] [Related]
50. Monitoring of low-molecular-weight heparins in cardiovascular disease.
Abbate R; Gori AM; Farsi A; Attanasio M; Pepe G
Am J Cardiol; 1998 Sep; 82(5B):33L-36L. PubMed ID: 9737479
[TBL] [Abstract][Full Text] [Related]
51. Inactivated antithrombins as fondaparinux antidotes: a promising alternative to haemostatic agents as assessed in vitro in a thrombin-generation assay.
Bourti Y; Fazavana J; Armand M; Saller F; Lasne D; Borgel D; Bianchini EP
Thromb Haemost; 2016 Aug; 116(3):452-60. PubMed ID: 27412396
[TBL] [Abstract][Full Text] [Related]
52. [An assay for anti-factor Xa activity of low molecular weight heparins by high performance liquid size exclusion chromatography].
Zhang Q; Kang J
Se Pu; 2013 Jul; 31(7):684-90. PubMed ID: 24164039
[TBL] [Abstract][Full Text] [Related]
53. A rationally designed heparin, M118, has anticoagulant activity similar to unfractionated heparin and different from Lovenox in a cell-based model of thrombin generation.
Volovyk Z; Monroe DM; Qi Y; Becker R; Hoffman M
J Thromb Thrombolysis; 2009 Aug; 28(2):132-9. PubMed ID: 19543696
[TBL] [Abstract][Full Text] [Related]
54. Oversulfated heparins with low anticoagulant activity are strong and fast inhibitors of hepcidin expression in vitro and in vivo.
Poli M; Asperti M; Ruzzenenti P; Mandelli L; Campostrini N; Martini G; Di Somma M; Maccarinelli F; Girelli D; Naggi A; Arosio P
Biochem Pharmacol; 2014 Dec; 92(3):467-75. PubMed ID: 25241290
[TBL] [Abstract][Full Text] [Related]
55. [Low molecular weight heparins. Implications in anesthesia and resuscitation].
Llau JV; Hoyas L; Ezpeleta J; García-Polit J; Barberá M; Santes MJ
Rev Esp Anestesiol Reanim; 1997 Feb; 44(2):70-8. PubMed ID: 9148359
[TBL] [Abstract][Full Text] [Related]
56. Generic low-molecular-weight heparins: some practical considerations.
Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
[TBL] [Abstract][Full Text] [Related]
57. Monitoring therapeutic anticoagulation with low molecular weight heparins: is it useful or misleading?
Hammerstingl C
Cardiovasc Hematol Agents Med Chem; 2008 Oct; 6(4):282-6. PubMed ID: 18855641
[TBL] [Abstract][Full Text] [Related]
58. The direct oral anticoagulants rivaroxaban and dabigatran do not inhibit orthotopic growth and metastasis of human breast cancer in mice.
Buijs JT; Laghmani EH; van den Akker RFP; Tieken C; Vletter EM; van der Molen KM; Crooijmans JJ; Kroone C; Le Dévédec SE; van der Pluijm G; Versteeg HH
J Thromb Haemost; 2019 Jun; 17(6):951-963. PubMed ID: 30929299
[TBL] [Abstract][Full Text] [Related]
59. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Hirsh J; Raschke R
Chest; 2004 Sep; 126(3 Suppl):188S-203S. PubMed ID: 15383472
[TBL] [Abstract][Full Text] [Related]
60. Novel concatameric heparin-binding peptides reverse heparin and low-molecular-weight heparin anticoagulant activities in patient plasma in vitro and in rats in vivo.
Schick BP; Maslow D; Moshinski A; San Antonio JD
Blood; 2004 Feb; 103(4):1356-63. PubMed ID: 14576044
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
